• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·ORCHPHARMA.NS
Share

Orchid Pharma Limited Stocks

₹ 934.65Last Updated 03.09.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

₹ 519.06M

₹ 934.65
Key Takeaways

Risk factor

Limited trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Orchid Pharma Limited is a pharmaceutical enterprise primarily focused on the creation, production, and distribution of various pharmaceutical goods within India. Its offerings include active pharmaceutical ingredients (APIs), bulk pharmaceutical materials, finished dosage forms, and nutraceuticals. The company's comprehensive API portfolio features both oral and injectable cephalosporins, alongside specialized products for human and animal health. Additionally, their antibiotic selection encompasses betalactam, macrolide, fluoroquinolone, and imidazole compounds. Beyond its domestic activities, Orchid Pharma Limited also engages in international commerce, exporting its products to approximately 40 countries globally. Established in 1992, the company maintains its corporate headquarters in Chennai, India. It officially adopted its current name, Orchid Pharma Limited, in October 2015, having previously been known as Orchid Chemicals & Pharmaceuticals Limited. Currently, it operates as a subsidiary under Dhanuka Laboratories Limited.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of ORCHPHARMA.NS is 928 and suggests 0.676% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommenda

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

04.09.2026 19:26

Despite "hawkish" signals from the labor market, Trump demanded that the Fed cut interest rates

04.09.2026 18:56

New Arguments in Favor of the "Hawks": Strong Employment Data Pushed the Dow Jones Down

04.09.2026 17:41

U.S. job growth in August was three times higher than expected. What will the Fed decide?

04.09.2026 17:18

The Dollar Faces a Triple Threat: Interest Rates, the Yen, and Hedging

04.09.2026 16:27

Where to Invest $1,000 in September: Betting on Gold, Entertainment, and Auto Parts

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026